The Therapeutic Good Administration has up to date GLP-1 RA product warnings due to their potential to trigger a uncommon however extreme eye dysfunction.
The glucagon-like peptide-1 receptor agonist (GLP-1 RAs) class of medicines are used to primarily deal with sort 2 diabetes and weight problems.
Rising proof means that semaglutide could also be related to a small enhance in threat, though absolutely the threat stays low.
Search pressing medical consideration in the event you expertise sudden lack of imaginative and prescient.
The attention dysfunction, non-arteritic anterior ischaemic optic neuropathy, is a uncommon situation which will lead to everlasting visible impairment, together with blindness, and no therapy has been proven to enhance visible acuity outcomes.
The GLP-1 RA class of medicines at the moment marketed in Australia are:
- Trulicity – (dulaglutide)
- Ozempic – (semaglutide)
- Wegovy – (semaglutide)
- Mounjaro – (tirzepatide)*
- Saxenda – (liraglutide)
* Tirzepatide is a twin glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RA.
Please observe this hyperlink for additional data: https://www.tga.gov.au/security/safety-monitoring-and-information/safety-alerts/glp-1-ras-and-rare-severe-eye-disorders
